摘要
吉兰-巴雷综合征(GBS)是一种急性自身免疫介导的周围神经病,是目前导致急性弛缓性瘫痪的主要病因之一。静脉注射免疫球蛋白和血浆置换是主要的免疫治疗方法。尽管经过免疫治疗,仍有相当一部分患者预后较差,可遗留严重功能障碍甚至死亡。因此寻找与预后相关的指标,开发有效的预测模型,有利于早期识别预后不佳患者,及早开始个体化治疗,改善预后。现总结近年GBS免疫治疗和预后评估方面的研究进展,旨在为临床诊疗提供参考。
Guillain-Barrésyndrome(GBS)is an acute onset immune-mediated polyradiculoneuropathy,and it is the most frequent cause of acute flaccid paralysis.Intravenous immunoglobulin and plasma exchange are proved to be an effective treatment.Despite the efficacy of immunotherapy,a significant number of patients have a poor prognosis,leaving behind severe dysfunction and even death.Therefore,biomarkers and prognostic models are needed to accurately predict outcome,which could help the early recognition of patients with poor outcomes,which may potentially be-nefit from individualized treatments.So,new development of immunotherapy and prognostic evaluation of GBS were summarized in this paper,in order to provide the evidence for clinical diagnosis and treatment.
作者
罗涵予
蒋莉
Luo Hanyu;Jiang Li(Department of Neurology,Children′s Hospital of Chongqing Medical University,Ministry of Education Key Laboratory of Child Development and Disorders,China International Science and Technology Cooperation Base of Child Development and Critical Disorders,Chongqing Key Laboratory of Pediatrics,Chongqing 400014,China)
出处
《中华实用儿科临床杂志》
CSCD
北大核心
2019年第24期1907-1910,共4页
Chinese Journal of Applied Clinical Pediatrics
